Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
4.5
Journals
Biomedicines
Special Issues
Advances in Chronic Respiratory System Diseases: From Bench to Bedside
share announcement

Advances in Chronic Respiratory System Diseases: From Bench to Bedside

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 November 2026 | Viewed by 375

Editor

Dr. Paolo Cameli

E-Mail Website
Guest Editor
Respiratory Disease Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Viale Bracci, 53100 Siena, Italy
Interests: interstitial lung disease; KL-6; lung transplant; vasculitis; myositis

Special Issue Information

Dear Colleagues,

A novel era in respiratory medicine is approaching. This Special Issue, “Advances in Chronic Respiratory System Diseases: From Bench to Bedside,” aims to provide a comprehensive overview of the latest scientific and clinical developments in the field of chronic respiratory disorders, including chronic obstructive pulmonary disease (COPD), asthma, and interstitial lung diseases.

The focus of this Special Issue is to bridge the gap between basic research and clinical application by highlighting translational studies that move from molecular and cellular mechanisms to innovative diagnostic tools and therapeutic strategies. Contributions explore key pathogenic pathways such as inflammation, oxidative stress, immune dysregulation, and tissue remodeling, alongside emerging roles of -omics sciences.

In addition, this collection emphasizes advances in precision medicine, novel pharmacological treatments, biologics, regenerative approaches, and digital health technologies for disease monitoring and management. Clinical studies, reviews, and experimental research addressing early diagnosis, disease phenotyping, and personalized interventions are particularly encouraged.

By promoting dialogue between bench scientists and clinicians, this Special Issue seeks to accelerate innovation and support the development of more effective, patient-centered strategies for the prevention, diagnosis, and treatment of chronic respiratory diseases.

Dr. Paolo Cameli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • severe asthma
  • COPD
  • bronchiectasis
  • translational medicine
  • molecular biomarkers
  • interstitial lung diseases
  • immunobiology
  • omics
  • prognosis
  • pathogenesis
  • genetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

14 pages, 422 KB  
Review
COPD Stability and Asthma Remission: Different Words for the Same Therapeutic Ambition?
by Lorenzo Carriera, Pier-Valerio Mari, Roberto Lipsi, Simone Ielo, Eugenio De Corso, Stefano Baglioni, Alberto Ricci and Luca Richeldi
Biomedicines 2026, 14(8), 1675; https://doi.org/10.3390/biomedicines14081675 - 25 Jul 2026
Viewed by 192
Abstract
The therapeutic goals related to chronic airway diseases are evolving from short-term symptom control toward sustained suppression of disease activity and prevention of future risk. In severe asthma, this shift has been captured by the concept of clinical remission, generally defined by absence [...] Read more.
The therapeutic goals related to chronic airway diseases are evolving from short-term symptom control toward sustained suppression of disease activity and prevention of future risk. In severe asthma, this shift has been captured by the concept of clinical remission, generally defined by absence of exacerbations, no need for oral corticosteroids, symptom control, and stable or improved lung function. In chronic obstructive pulmonary disease (COPD), the analogous concept has more often been described as disease stability. Although remission in asthma and stability in COPD have developed within different biological and clinical frameworks, they may reflect disease-specific expressions of the same therapeutic ambition. Recent studies support COPD stability as a measurable and clinically meaningful state, associated with reduced exacerbation risk and mortality. Evidence from optimized inhaled triple therapy, particularly with fluticasone furoate/umeclidinium/vilanterol, indicates that multidimensional stability can be achieved and maintained in a proportion of patients, while real-world studies reinforce its applicability beyond randomized trials. The emergence of biologic therapies for selected patients with eosinophilic or type 2 COPD further strengthens the rationale for considering stability as an ambitious treatment target. In this narrative review, informed by a structured literature search, we discuss the conceptual relationship between asthma remission and COPD stability, and summarize the evidence supporting disease stability as an attainable and prognostically relevant outcome. In addition, we propose a pragmatic multidimensional definition based on symptom stability, absence of moderate or severe exacerbations, no systemic corticosteroid use, and maintained lung function over 12 months. COPD stability should not be viewed as a weaker goal than asthma remission, but rather as the most appropriate COPD-specific expression of sustained low disease activity. Full article
(This article belongs to the Special Issue Advances in Chronic Respiratory System Diseases: From Bench to Bedside)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop